<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Protein C deficiency</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Protein C deficiency</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Protein C deficiency</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth A Bauer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Protein C deficiency is associated with a small percentage of cases of inherited thrombophilia, as well as the even more uncommon findings of warfarin-induced skin necrosis and neonatal purpura fulminans. However, establishing a diagnosis of hereditary protein C deficiency can be difficult, as many clinical states can lead to acquired protein C deficiency.</p><p>This topic review discusses the diagnosis and management of protein C deficiency (inherited and acquired).</p><p>Separate topic reviews address the appropriate use of thrombophilia testing in various clinical settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Children – (See  <a class="medical medical_review" href="/d/html/5920.html" rel="external">"Thrombophilia testing in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with VTE – (See  <a class="medical medical_review" href="/d/html/1363.html" rel="external">"Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with stroke – (See  <a class="medical medical_review" href="/d/html/1083.html" rel="external">"Overview of the evaluation of stroke", section on 'Blood tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with pregnancy loss – (See  <a class="medical medical_review" href="/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'Selection of patients for testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic patients with a positive family history – (See  <a class="medical medical_review" href="/d/html/1364.html" rel="external">"Screening for inherited thrombophilia in asymptomatic adults"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span></p><p class="headingAnchor" id="H1436028973"><span class="h2">Biology of protein C</span><span class="headingEndMark"> — </span>Protein C is a vitamin K-dependent anticoagulant protein synthesized in the liver. It has a molecular weight of about 62 kilodaltons (kD) and consists of two chains connected by a disulfide bridge.</p><p>Protein C circulates as a zymogen and exerts its anticoagulant function after activation to activated protein C (aPC), a serine protease [<a href="#rid1">1</a>]. This process occurs when thrombin is bound to thrombomodulin, a specific receptor on vascular endothelium (<a class="graphic graphic_figure graphicRef110320" href="/d/graphic/110320.html" rel="external">figure 1</a>). Synthesis of gamma-carboxyglutamic acid (Gla) in protein C requires <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a>. The Gla domain binds calcium, leading to a structural change that facilitates phospholipid binding, which is important for protein C function.</p><p>The primary role of aPC is to inactivate coagulation factors Va and VIIIa, which are necessary for efficient thrombin generation and factor X activation, respectively [<a href="#rid1">1</a>]. The inhibitory effect of aPC is enhanced by protein S, another vitamin K-dependent anticoagulant protein. Inherited deficiency of protein C can lead to thrombophilia (increased tendency toward thrombosis). (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Control mechanisms and termination of clotting'</a>.)</p><p>In addition to its anticoagulant function in the coagulation pathway, aPC has a role in counteracting inflammation. By binding to the endothelial protein C receptor (EPCR) and protease-activated receptor-1 (PAR1), aPC exerts cytoprotective effects on cells, including anti-inflammatory activity and endothelial barrier protection [<a href="#rid2">2,3</a>].</p><p>After birth, levels of protein C take some time to reach normal adult levels. Preterm infants have protein C levels of approximately 7 to 18 percent of normal, while full term newborns have protein C levels of 20 to 40 percent of normal [<a href="#rid4">4-7</a>]. Neonates with significant thrombosis can have extremely low levels (low enough to suggest homozygous deficiency) that normalize upon recovery from the event [<a href="#rid8">8</a>]. Protein C levels increase during normal aging [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>Most patients with inherited protein C deficiency are heterozygous. Over 195 different mutations in the protein C gene (<em>PROC</em>) have been described [<a href="#rid10">10-13</a>]. The gene is located on chromosome 2 (2q13-14) [<a href="#rid14">14,15</a>].</p><p>Inherited protein C deficiency can be subdivided according to whether the deficient activity is due to reduced protein levels (type I) or to reduced protein function (type II). Type I deficiency is more common than type II deficiency; there do not appear to be clinical differences between type I and type II protein C deficiencies.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type I</strong> – Type I deficiency (reduced protein C antigen and activity levels) is most commonly caused by a missense or nonsense mutation (encoding an alternate amino acid or a premature stop codon, respectively) [<a href="#rid10">10,11,16</a>]. Other types of mutations have also been described, including promoter mutations, splice site abnormalities, in-frame deletions, frameshift deletions, in-frame insertions, and frameshift insertions [<a href="#rid10">10</a>]. These defects can reduce the production of protein C or accelerate its destruction. The plasma protein C level is approximately 50 percent of normal, as measured in immunologic and functional assays [<a href="#rid10">10</a>]. Despite the similar protein C activity level in most patients with type I deficiency, there is marked phenotypic variability among patients. Similar mutations have been found among symptomatic and asymptomatic individuals, implying that the nature of the protein C gene defect alone does not explain the phenotypic variability [<a href="#rid11">11,17,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type II</strong> – Type II deficiency (reduced protein C function with normal antigen levels) is caused by mutations that affect the amino acid sequence of protein C and in turn inhibit the ability of protein C to carry out its anticoagulant function. A variety of different point mutations affecting protein function have been described [<a href="#rid10">10,19</a>].</p><p></p><p>Although less common than the heterozygous state, some individuals are homozygous or compound heterozygous for disease variants in the protein C gene; this is due to inheritance of a variant allele from both parents. Severe deficiency of protein C (ie, level &lt;1 percent) can lead to neonatal purpura fulminans at birth. (See <a class="local">'Neonatal purpura fulminans management'</a> below.) </p><p>This was demonstrated in a 2017 series of 22 individuals who were homozygous or compound heterozygous for a protein C disease variant, in which 16 (73 percent) presented with neonatal purpura fulminans, intracranial thromboembolism, or both [<a href="#rid20">20</a>]. Six others with a higher plasma protein C level (approximately 30 percent) developed thrombosis after age 15. Other individuals can have genetic variants leading to protein C levels &lt;20 percent of normal; they are at risk for more severe phenotypes than heterozygous individuals. These <em>PROC</em> variants are collated in various databases [<a href="#rid10">10,21</a>]. (See <a class="local">'Clinical features'</a> below.)</p><p>The coinheritance of protein C deficiency and another thrombophilic variant such as factor V Leiden is also occasionally seen and increases thromboembolic risk, although high-quality evidence is lacking regarding the magnitude of the combined effect. (See <a class="local">'Venous thromboembolism'</a> below.)</p><p class="headingAnchor" id="H2448339446"><span class="h2">Control of protein C levels</span></p><p class="headingAnchor" id="H2031285438"><span class="h3">Normal levels</span><span class="headingEndMark"> — </span>Protein C circulates in human plasma at an average concentration of 4 mcg/mL. The concentrations of protein C are normally distributed in healthy adults with 95 percent of the values ranging between 70 to 140 percent of normal [<a href="#rid9">9</a>]. There is no significant sex difference. </p><p class="headingAnchor" id="H1011500281"><span class="h3">Causes of reduced protein C</span><span class="headingEndMark"> — </span>In addition to the role of protein C gene mutations, circulating levels of protein C may be reduced in a number of conditions that affect protein C synthesis (typically, acute insults to the liver such as right heart failure with hepatic congestion, severe liver disease, or disseminated intravascular coagulation [DIC]) [<a href="#rid6">6,22</a>]. Protein C levels are also generally lower than normal in the setting of acute inflammation, which may explain reduced levels in trauma/surgery or acute respiratory distress syndrome. There is little evidence that acute thrombosis by itself lowers protein C levels. As noted above, neonates have lower-than-normal levels of protein C, and protein C levels increase modestly during normal aging. (See <a class="local">'Biology of protein C'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>DIC</strong> – Patients with DIC have ongoing consumption of coagulation factors and natural anticoagulants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver disease</strong> – Patients with severe liver disease have reduced circulating levels of all of the natural anticoagulants produced by the liver, including protein C [<a href="#rid23">23</a>]. However, these changes are counterbalanced by corresponding changes in procoagulant factors, leading to a state of "rebalanced" hemostasis. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Protein C levels are not generally affected by infection. However, a particularly severe form of acquired protein C deficiency has been described in certain patients with acute viral, bacterial, and other infections (eg, malaria) [<a href="#rid24">24</a>]. Meningococcemia is probably the best characterized of these [<a href="#rid25">25,26</a>]. In these cases administration of <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a> may be helpful, similar to the management of neonatal purpura fulminans [<a href="#rid25">25,27,28</a>]. (See  <a class="medical medical_review" href="/d/html/5911.html" rel="external">"Neonatal thrombosis: Management and outcome", section on 'Neonatal purpura fulminans'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uremia</strong> – Most uremic patients have low levels of protein C anticoagulant activity despite normal levels of protein C amidolytic activity and protein levels [<a href="#rid29">29</a>]. This is thought to be due to a dialyzable substance in uremic plasma that interferes with most clotting assays for protein C activity [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer or cancer therapy</strong> – A syndrome of venous limb ischemia with gangrene has been described in 10 patients with cancer who were treated with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid30">30</a>]. The affected individuals had evidence of reduced coagulation factor VII and protein C activity.</p><p></p><p class="bulletIndent1">Some cancer chemotherapeutic agents such as asparaginase cause reductions in protein C levels. Hormonal agents have also been reported to alter protein C levels, though studies are less consistent with respect to the observed effects. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">Vitamin K</a><strong> antagonists</strong> – Vitamin K antagonist (VKA) anticoagulants (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) interfere with protein C production and maturation, as well as protein S. This has implications for diagnostic testing and patient management:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnostic testing</strong> – Testing for protein C deficiency generally should not be performed if the patient is receiving a VKA anticoagulant, regardless of the type of assay. (See <a class="local">'Timing/effects of anticoagulants'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management </strong>– The reduction of protein C levels by <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> produces a transient procoagulant state, since protein C has a shorter half-life than the other vitamin K-dependent factors (except for factor VII) and thus is depleted more rapidly. This is of no clinical consequence to the vast majority of patients. However, it is responsible for the increased risk of the rare complication of warfarin-induced skin necrosis in individuals with hereditary protein C deficiency; this provides the rationale for administration of a source of protein C (either with Fresh Frozen Plasma [FFP] or <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a>) to patients suspected of having this thrombotic complication. (See <a class="local">'Management'</a> below.)</p><p></p><p class="bulletIndent1">In contrast with reduced protein C levels with <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> antagonists, other anticoagulants such as heparin, direct thrombin inhibitors, direct oral factor Xa inhibitors, and <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> do not affect circulating protein C levels. However, as noted below, the direct oral anticoagulants may interfere in assays for protein C activity with clotting endpoints. (See <a class="local">'Timing/effects of anticoagulants'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">Vitamin K</a><strong> deficiency</strong> – Patients with vitamin K deficiency have a defect that resembles the use of a VKA anticoagulant. Common causes of deficiency include severe malnutrition and antibiotic use. (See  <a class="medical medical_review" href="/d/html/2624.html" rel="external">"Overview of vitamin K", section on 'Vitamin K deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoantibodies</strong> – A case of an acquired inhibitor of protein C has been reported in an Australian patient [<a href="#rid31">31</a>]. This individual had a bleeding diathesis for several years and developed purpura fulminans before his death. Autopsy revealed arterial and venous thrombi in many organs. The IgG fraction of the patient's plasma completely inhibited the functional anticoagulant activity of activated protein C.</p><p></p><p>Although these conditions can transiently reduce protein C levels, the reduction is typically modest, and these patients generally should not be considered to have protein C deficiency for diagnostic or therapeutic purposes (ie, we do not consider them to be in the same category as individuals with inherited protein C deficiency with respect to their risk of thrombosis). An exception is a patient with severe clinical manifestations such as purpura fulminans and DIC in acute meningococcemia; in such cases administration of <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a> may be beneficial. (See  <a class="medical medical_review" href="/d/html/5911.html" rel="external">"Neonatal thrombosis: Management and outcome", section on 'Neonatal purpura fulminans'</a>.)</p><p>Despite the reduced levels of protein C seen in acute inflammatory states, administration of <strong>activated</strong> protein C was shown to be ineffective for the treatment of sepsis, as discussed separately. (See  <a class="medical medical_review" href="/d/html/1631.html" rel="external">"Investigational and ineffective pharmacologic therapies for sepsis"</a>.)</p><p class="headingAnchor" id="H1966618936"><span class="h3">Causes of increased protein C</span><span class="headingEndMark"> — </span>Protein C levels may be increased in the following settings; these increases generally do not affect patient management but are worth noting if the level is slightly above the threshold for deficiency:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nephrotic syndrome</strong> – Patients with nephrotic syndrome often have elevated levels of protein C [<a href="#rid32">32-34</a>]. It appears the hypercoagulable state is due to effects on other hemostatic factors. (See  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperlipidemia</strong> – Patients with hyperlipidemia may have increased protein C levels. In one study of 150 adults, mean levels of protein C activity rose approximately 25 percent as total cholesterol and triglyceride levels increased from the 5th to the 95th percentile [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal aging</strong> – Normal aging is associated with modest increases in protein C levels (by approximately 4 percent per decade).</p><p></p><p class="headingAnchor" id="H2299333195"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of inherited protein C deficiency varies depending on the population (<a class="graphic graphic_table graphicRef108016" href="/d/graphic/108016.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Healthy individuals in the general population – Approximately 0.2 to 0.5 percent [<a href="#rid9">9,36</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with venous thromboembolism (VTE) – Approximately 2 to 5 percent [<a href="#rid37">37-39</a>].</p><p></p><p>Data from which these incidence numbers were derived include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>General healthy population</strong> – In two series of healthy adults (eg, blood donors, volunteers), protein C deficiency was documented in 10 of 5422 (0.18 percent; 1 in 555) and in 14 of 9854 (0.14 percent; 1 in 714) [<a href="#rid9">9,36</a>]. Both studies noted that there is not a strict cutoff between heterozygotes and unaffected individuals, so the true number of heterozygotes could be higher or lower. Additionally, the larger study noted that protein C levels fluctuated over time and between readings such that individuals with borderline levels sometimes met criteria for protein C deficiency and sometimes did not [<a href="#rid36">36</a>]. None of the protein C-deficient individuals identified by population screening had a clinical history of VTE. Also of note, some of the individuals with true protein C deficiency in the larger study had genetic testing and family studies performed and were identified as the index case of a new genetic defect [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with VTE</strong> – In a series of 2132 consecutive individuals presenting with VTE in Spain, 68 (3.2 percent) had protein C deficiency [<a href="#rid37">37</a>]. In another series of 277 outpatients who presented with an acute VTE, nine (3.3 percent) had protein C deficiency [<a href="#rid39">39</a>]. In both of these series, protein C deficiency was more common than antithrombin (AT) deficiency; protein C deficiency was slightly more common than protein S deficiency in one and slightly less common than protein S deficiency in the other. The frequency of the factor V Leiden mutation in these cohorts, which is now known to be much more common than these deficiencies, was not evaluated.</p><p></p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>There is considerable phenotypic variability among individuals with protein C deficiency with respect to the development of symptomatic venous thrombosis. The overall relative risk of thrombosis with heterozygous protein C deficiency is approximately seven times that of individuals without an inherited thrombophilia (<a class="graphic graphic_table graphicRef108016" href="/d/graphic/108016.html" rel="external">table 1</a>) [<a href="#rid40">40,41</a>]. It has also been suggested that there is an association of protein C deficiency with arterial thromboembolism (eg, stroke).</p><p class="headingAnchor" id="H7"><span class="h2">Venous thromboembolism</span><span class="headingEndMark"> — </span>Individuals with protein C deficiency can develop venous thromboembolism (VTE) at any site; thrombosis in the deep veins of the leg (DVT), mesenteric veins, and pulmonary embolism (PE) are the most common. VTE can also affect other sites including cerebral veins, portal vein, superficial or other unusual sites [<a href="#rid40">40,42-44</a>]. As noted above, the risk of thrombosis with heterozygous protein C deficiency is increased approximately sevenfold (<a class="graphic graphic_table graphicRef108016" href="/d/graphic/108016.html" rel="external">table 1</a>) [<a href="#rid40">40,41</a>]. </p><p>The absolute risk of VTE in a patient with protein C deficiency is difficult to estimate because other modifying factors also contribute to risk; family history of VTE or other clinical events is the best predictor. Among thrombophilic families, the risk of thrombosis in individuals with protein C deficiency is similar to that of protein S deficiency and antithrombin (AT) deficiency (approximately 1 thrombosis per 100 patient-years), and higher than individuals with the factor V Leiden mutation (approximately 0.3 thromboses per 100 patient-years) [<a href="#rid40">40</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>The absolute risk of VTE in individuals with a positive family history may be as high as 75 percent in severely affected families and closer to 30 percent in other families [<a href="#rid40">40,42,45,46</a>]. In a series that included 46 protein C-deficient individuals, there were 13 thromboses (28 percent), compared with five thromboses in 138 unaffected relatives (4 percent) [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regardless of family history, the risk of VTE in individuals with protein C deficiency is expected to be increased by additional inherited or acquired VTE risk factors (eg, factor V Leiden mutation, prolonged immobility, surgery, oral hormonal contraceptive use) [<a href="#rid44">44,48-50</a>]. In one series that included 15 individuals with protein C deficiency, six (40 percent) also had the factor V Leiden mutation, a higher proportion than would be expected in the general population [<a href="#rid49">49</a>]. Compared with the individuals with isolated protein C deficiency, those with combined protein C deficiency and factor V Leiden mutation had an earlier onset of thrombosis (mean age of onset, 32 versus 18 years) and a greater risk of thrombosis. Other uncharacterized genetic modifiers may also increase VTE risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The initial episode of VTE in patients with protein C deficiency is apparently spontaneous in approximately two-thirds of cases, and the remaining third have the usual risk factors (eg, pregnancy, parturition, oral contraceptives, surgery, or trauma). In a series of 22 patients with protein C deficiency, 15 (68 percent) had a history of VTE.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The age of a first thromboembolic event can be in young adulthood. Individuals with a positive family history are more likely to have a first VTE in their 20s to 30s, while individuals without a family history of thrombophilia are more likely to have a first VTE in their 30s to 40s [<a href="#rid49">49,51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of recurrent thrombosis depends on the clinical setting but is thought to be approximately 60 percent in patients from thrombophilic families without prophylactic anticoagulation [<a href="#rid52">52</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Warfarin-induced skin necrosis</span><span class="headingEndMark"> — </span>Warfarin-induced skin necrosis is a complication of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy in which the patient develops demarcated areas of purpura and necrosis due to vascular occlusion. The appearance may be similar to that of neonatal purpura fulminans and may affect one or more areas of skin including the extremities, breasts, trunk, or penis (<a class="graphic graphic_picture graphicRef80462" href="/d/graphic/80462.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef53920" href="/d/graphic/53920.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef57103" href="/d/graphic/57103.html" rel="external">picture 3</a>).</p><p>The mechanism of warfarin-induced skin necrosis involves a transient hypercoagulable state during initial <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> administration that in turn leads to vascular occlusion and tissue infarction followed by extravasation of blood. (See  <a class="medical medical_review" href="/d/html/16556.html" rel="external">"Approach to the patient with retiform (angulated) purpura", section on 'Thrombotic and coagulopathic disorders'</a>.)</p><p>The half-lives vary among the vitamin K-dependent coagulation factors (factors II, VII, IX, and X) and natural anticoagulants (protein S and protein C), and as a result, the factors with the shorter half-lives (half-lives for factor VII and protein C of 8 and 14 hours, respectively) are depleted more rapidly than the others (<a class="graphic graphic_figure graphicRef50940" href="/d/graphic/50940.html" rel="external">figure 2</a>) [<a href="#rid53">53</a>]. Laboratory studies of thrombin generation using an assay for the activation of prothrombin using the generation of fragment F1+2 have suggested that effects on protein C (ie, a procoagulant effect) predominate over effects on factor VII in vivo [<a href="#rid54">54</a>].</p><p>The skin lesions in warfarin-induced skin necrosis typically form during the first few days of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy, often in the setting of large loading doses of 10 or more milligrams of warfarin per day [<a href="#rid55">55-57</a>]. If the patient is receiving heparin and warfarin therapy, the lesions may appear upon discontinuation of the heparin [<a href="#rid58">58</a>]. Lesions appear in the absence of heparin because the early effect of warfarin is procoagulant. </p><p>The lesions typically marginate over a period of hours from an initial central erythematous macule, similar to neonatal purpura fulminans. If a product containing protein C is not rapidly administered, the affected cutaneous areas become edematous, develop central purpuric zones, and ultimately become necrotic. Biopsy of the lesions is not generally performed, but if a biopsy is obtained it may show diffuse microthrombi within dermal and subcutaneous capillaries, venules, and deep veins, with endothelial cell damage, resulting in ischemic skin necrosis and marked red blood cell extravasation [<a href="#rid59">59</a>]. These findings are indistinguishable from other thrombotic skin lesions including antiphospholipid syndrome (APS), disseminated intravascular coagulation (DIC), and heparin-induced thrombocytopenia (HIT).</p><p>The incidence of warfarin-induced skin necrosis in individuals with protein C deficiency is unknown, as most descriptions are in the form of case reports. Warfarin-induced skin necrosis is not pathognomonic for protein C deficiency; it has been described in individuals with other inherited thrombophilias (factor V Leiden mutation, protein S deficiency) and transient reductions of protein C levels (eg, in the setting of cancer) [<a href="#rid60">60-62</a>]. (See <a class="local">'Causes of reduced protein C'</a> above.)</p><p>As noted, immediate interventions should include the discontinuation of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and the administration of intravenous <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> to reverse warfarin as well as a source of protein C (either Fresh Frozen Plasma [FFP] or <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a>) in order to minimize the extent of skin necrosis. (See <a class="local">'Management'</a> below.)</p><p class="headingAnchor" id="H547188449"><span class="h2">Neonatal purpura fulminans</span><span class="headingEndMark"> — </span>Purpura fulminans in newborns is a rare, life-threatening condition characterized by disseminated intravascular coagulation (DIC), extensive venous and arterial thrombosis, and hemorrhagic skin necrosis. It usually is caused by a homozygous or compound heterozygous deficiency in protein C, as discussed above (see <a class="local">'Genetics'</a> above). Laboratory testing reveals evidence of disseminated intravascular coagulation and extremely low protein C levels of under 1 percent of normal. Diagnosis and management of this disorder, including the use of <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a>, are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5912.html" rel="external">"Neonatal thrombosis: Clinical features and diagnosis", section on 'Purpura fulminans'</a> and  <a class="medical medical_review" href="/d/html/5911.html" rel="external">"Neonatal thrombosis: Management and outcome", section on 'Neonatal purpura fulminans'</a>.)</p><p class="headingAnchor" id="H2090035353"><span class="h2">Arterial thrombosis/stroke</span><span class="headingEndMark"> — </span>The risk of arterial thrombosis in patients with protein C deficiency may be increased slightly, but high-quality data are lacking to support or refute an association. Ischemic stroke has been reported in young adults (heterozygotes) with hereditary protein C deficiency [<a href="#rid63">63-65</a>]. It is difficult to establish whether the rate of stroke is actually increased in individuals with protein C deficiency. Larger studies have not convincingly demonstrated that protein C deficiency is a risk factor for the development of arterial thrombosis [<a href="#rid66">66-68</a>]. In one series, for example, antithrombin, protein C, and protein S levels were measured in 127 consecutive patients with a mean age of 34 years admitted for an ischemic stroke [<a href="#rid66">66</a>]. Abnormal anticoagulant protein levels were found in nine patients. However, seven of these patients had an acquired cause of deficiency, such as pregnancy or estrogen administration, and the other two patients had transiently low levels in the absence of an obvious acquired cause.</p><p class="headingAnchor" id="H16"><span class="h2">Fetal loss</span><span class="headingEndMark"> — </span>Protein C deficiency has been linked to fetal loss, but thrombophilia is not thought to be a major factor in most adverse pregnancy outcomes (miscarriage, fetal loss, preeclampsia, fetal growth impairment) [<a href="#rid69">69-71</a>]. (See  <a class="medical medical_review" href="/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'Adverse pregnancy outcome risk'</a>.)</p><p>In a report from the European Prospective Cohort on Thrombophilia that compared pregnancies in 843 women with thrombophilia and 541 controls (unaffected partners of men in the cohort), the risk of fetal loss (miscarriage or stillbirth) was slightly increased in the thrombophilic women (odds ratio [OR] 1.35, 95% CI 1.01-1.82) [<a href="#rid69">69</a>]. The highest risk for stillbirth was in women with more than one thrombophilic defect. For the 162 women in this cohort with protein C deficiency, the numbers were too small to reach statistical significance (OR 1.4, 95% CI 0.9-2.2). The role (or lack thereof) of prophylactic anticoagulation to prevent pregnancy complications, as well as increased fetal surveillance and timing of delivery, are discussed separately. (See  <a class="medical medical_review" href="/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'Prevention of pregnancy complications'</a>.)</p><p>However, it is important to note that pregnancy increases the risk of VTE due to a number of physiologic and anatomic changes, and prophylactic anticoagulation during pregnancy and the postpartum period to reduce the risk of VTE is appropriate for certain individuals with protein C deficiency. This subject is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'Prevention of VTE'</a> and  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H951289643"><span class="h2">Overview of diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of protein C deficiency may be suspected in a patient with recurrent venous thrombosis, thrombosis in an unusual vascular bed (eg, portal, hepatic, mesenteric, cerebral), thrombosis at a young age (eg, &lt;50 years), strong family history of venous thromboembolism (VTE), and/or warfarin-induced skin necrosis.</p><p>The diagnosis of protein C deficiency is established by documenting low protein C levels. In most cases, levels are approximately 50 percent of normal. However, the absolute threshold for deficiency is not clear. In a series of 28 individuals identified as members of a protein C-deficient family for whom pedigree analysis established that they personally inherited the familial defect, the range of protein C values was wide (median activity level 53 percent, range 19 to 82 percent; median antigen level 54 percent, range 22 to 89 percent) [<a href="#rid72">72</a>]. Most laboratories set the threshold for deficiency below 65 to 70 percent of normal [<a href="#rid47">47</a>]. <span class="utd-adt-cnt utd-adt-labi">(Related Lab Interpretation Monograph(s):  <a class="narrative narrative_labi" href="/contents/low-protein-c-in-adults?topicRef=1354&amp;source=see_link">"Low protein C in adults"</a>.)</span></p><p>Individuals with a protein C level below 55 percent of normal are very likely to have a genetic abnormality, while levels from 55 to 65 percent are consistent with either a deficiency state or the lower end of the normal distribution [<a href="#rid9">9</a>].</p><p>Measures to improve the usefulness and accuracy of laboratory testing include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Testing ideally should be done after the patient has recovered from an acute event such a severe inflammatory illness. If the result was obtained at the time of one of these events, it is prudent to repeat the testing. (See <a class="local">'Causes of reduced protein C'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The possible interference from an anticoagulant, especially <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, should be taken into account when ordering protein C testing, based on the medication list and the patient’s prothrombin time (PT) and international normalized ratio (INR). (See <a class="local">'Assays'</a> below and <a class="local">'Timing/effects of anticoagulants'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age-appropriate and laboratory-specific normal values should be consulted for infants and young children because protein C levels are lower at birth and take time to reach adult levels. (See <a class="local">'Biology of protein C'</a> above.)</p><p></p><p>In contrast to patients with a personal or family history of VTE before age 50, we do not routinely suspect protein C deficiency in an individual ≥50 years of age with a first episode of VTE in a typical location (eg, deep vein of the leg, pulmonary embolism) unless there is a strong family history of thrombophilia.</p><p class="headingAnchor" id="H18"><span class="h2">Assays</span><span class="headingEndMark"> — </span>A variety of assay methods have been developed to measure protein C activity or protein levels in plasma samples. The preferred method is a functional assay because a functional assay will detect reduced protein levels as well as defective protein C function with normal protein levels (type I and type II defects). (See <a class="local">'Genetics'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Available functional assays for protein C include an aPTT-based assay, a factor Xa-based assay, or an enzymatic assay using a chromogenic substrate (eg, amidolytic cleavage of a synthetic peptide substrate). The venom of a copperhead snake <em>Agkistrodon contortrix </em>(Protac) is used to activate protein C, although other activators such as thrombin or thrombin-thrombomodulin have also been used [<a href="#rid53">53,73,74</a>]. Amidolytic assays are frequently preferred by hospital laboratories because they have better performance characteristics than clotting assays.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The procedures for protein C antigen determination include various types of immunoassays [<a href="#rid75">75</a>]. The use of such assays will assist in characterizing patients as having a type I (reduced protein level and function) or type II (normal protein level, reduced function) defect; however, as noted above, this is not necessary for clinical management. (See <a class="local">'Genetics'</a> above.)</p><p></p><p>As a general rule, the clotting-based assays (aPTT or factor Xa-based) may be affected by anticoagulants including heparins, whereas the chromogenic assays generally are unaffected by anticoagulants, with the exception of <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> antagonists, which can lower activity in any assay. Clotting-based assays may occasionally identify a type II defect that was missed by an amidolytic assay. (See <a class="local">'Timing/effects of anticoagulants'</a> below.)</p><p>As with all coagulation testing, the test must be done using plasma (not serum). (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Ensuring accuracy'</a>.)</p><p>If a functional assay does not reveal reduced protein function but clinical suspicion is extremely high, it may be worthwhile to use an alternative type of functional assay.</p><p class="bulletIndent1"><span class="glyph">●</span>Several individuals have been described with normal protein C antigen measurements who have substantial reductions in protein C anticoagulant activity, but normal or near normal amidolytic activity [<a href="#rid53">53</a>]. These defects may reflect a reduced ability of activated protein C to interact with platelet membranes or its substrates such as factor V and factor VIII. The molecular abnormality in one of these families has been determined and is characterized by two gamma-carboxyglutamic acid (Gla) domain mutations (Glu20 to Ala and Val34 to Met) [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/d/html/1318.html" rel="external">"Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other patients have abnormal protein C molecules that are normally activated by the thrombin-thrombomodulin complex, but fail to exhibit proteolytic activity as measured by amidolytic or anticoagulant assays [<a href="#rid77">77,78</a>]. These patients may have mutations near the active site of the protein.</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Timing/effects of anticoagulants</span><span class="headingEndMark"> — </span>As noted above, an important consideration in laboratory testing for protein C deficiency is the possibility of erroneous diagnosis due to interference of an anticoagulant or an acute thrombosis or other illness. (See <a class="local">'Overview of diagnosis'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> – Warfarin (or other <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> antagonist [VKA]) reduces functional and, to a lesser extent, antigenic measures of protein C [<a href="#rid45">45,53,73,79,80</a>]. In practice, it is preferable to perform testing at least two weeks after the last dose of the VKA. If it is not possible to discontinue the VKA for clinical reasons, it may be possible to transition the patient to heparin or low molecular weight (LMW) heparin prior to testing. However, if the protein C level is tested and found to be normal during warfarin therapy, this effectively excludes protein C deficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heparins</strong> – Heparins (unfractionated or LMW) may interfere with clotting-based protein C assays.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">Fondaparinux</a> – Fondaparinux may interfere with clotting-based protein C assays.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct thrombin inhibitors</strong> – Direct thrombin inhibitors (DTIs; eg, <a class="drug drug_general" data-topicid="8765" href="/d/drug information/8765.html" rel="external">argatroban</a>, <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>) do not cause abnormal results of functional assays using snake venom to activate protein C and a chromogenic substrate to measure enzymatic activity. However, DTIs may interfere with functional assays using a clotting-based endpoint (eg, aPTT-based assays). DTIs do not interfere with antigenic assays of protein C.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct factor Xa inhibitors</strong> – Direct factor Xa inhibitors (eg, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>) do not cause abnormal results of functional assays using snake venom to activate protein C and a chromogenic substrate to measure enzymatic activity. However, these agents may interfere with functional assays using a clotting-based endpoint (eg, aPTT-based assays). These agents do not interfere with antigenic assays of protein C.</p><p></p><p>Consultation with the testing laboratory regarding the types of tests used (and available alternatives) is advised.</p><p>Several research laboratories have used a reduced ratio of protein C antigen to prothrombin or factor X antigen to identify patients with a type I deficiency state [<a href="#rid45">45,80</a>]. However, this approach can only be used in individuals who are in a stable phase of anticoagulation, and the diagnostic criteria for the disorder vary with the intensity of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy [<a href="#rid80">80</a>]. Other groups have successfully used protein C activity assays in conjunction with functional and antigenic measurements of factor VII, a vitamin K-dependent factor with a similar plasma half-life to protein C [<a href="#rid81">81-83</a>].</p><p class="headingAnchor" id="H2336334697"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>Genetic testing for mutations and other defects in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F612283&amp;token=87jLzclRwWxNoI%2BQq5Gg77LFquASCqO5OYSv7r6FmBCFszcOIY6VrYk0iEiAPleI&amp;TOPIC_ID=1354" target="_blank">PROC</a> gene, which encodes protein C, is not available for routine clinical use. A listing of research laboratories that perform this testing is available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2Fall%2Flabs%2F%3Fterm%3DC2674321%255BDISCUI%255D&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryxPkJNKdBG7Cjp%2BIy%2FGhti27zhnEvaSYkgFpH31WEyHP2efmDYGk9Aj2mSPOSTfo8%3D&amp;TOPIC_ID=1354" target="_blank">Genetic Testing Registry</a>.</p><p class="headingAnchor" id="H3523424538"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of venous thromboembolism (VTE) includes other inherited thrombophilias and acquired risk factors for thrombosis. The differential diagnosis of skin necrosis includes vascular lesions and heparin-induced thrombocytopenia (HIT).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other inherited thrombophilias</strong> – Other inherited thrombophilias include factor V Leiden mutation, protein S deficiency, antithrombin (AT) deficiency, and prothrombin G20210A mutation (<a class="graphic graphic_table graphicRef108016" href="/d/graphic/108016.html" rel="external">table 1</a>); of these, factor V Leiden is the most common. Like protein C deficiency, patients may present with a positive personal or family history of VTE, warfarin-induced skin necrosis, or other thromboembolic complications and often are treated with indefinite anticoagulation if one of these clinical events occurs. Unlike protein C deficiency, individuals with these other inherited thrombophilias will have laboratory evidence of the other specific defect and will have normal protein C levels, unless tested in the setting of acute illness or interfering anticoagulant. (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Inherited thrombophilia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired VTE risk factors</strong> – A number of acquired risk factors for VTE have been described, including immobility, surgery, trauma, cancer or myeloproliferative neoplasms (MPN), certain drugs, the antiphospholipid syndrome, paroxysmal nocturnal hemoglobinuria (PNH), disseminated intravascular coagulation (DIC), and hormonal changes including hormonal contraceptives, pregnancy, and the postpartum period. Like protein C deficiency, these patients may have VTE in typical or atypical locations. Unlike protein C deficiency, these acquired risk factors are often obvious from other features of the patient history and physical examination, and the family history typically does not reveal thrombophilia in these acquired disorders. (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Acquired risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes of skin necrosis</strong> – Skin necrosis (or a similar-appearing finding) can occur in the setting of a number of vascular lesions including cryoglobulinemia, vasculitis, septic or cholesterol emboli, levamisole-contaminated cocaine, and calciphylaxis; or with other anticoagulants such as heparin. Like protein C deficiency, these other disorders may occur in a hospitalized patient who may be receiving an anticoagulant and may be associated with dramatic and life-threatening infarction in the skin and internal organs. Unlike patients with protein C deficiency, individuals with other forms of skin necrosis often have other findings of vasculitis or other clinical or skin biopsy findings of vascular inflammation, organ damage, or infection. Unlike patients with protein C deficiency, individuals with HIT usually have thrombocytopenia and a clear temporal relationship with heparin exposure, and individuals with calciphylaxis typically have end-stage kidney disease and bilateral skin findings in the upper extremities. (See  <a class="medical medical_review" href="/d/html/16556.html" rel="external">"Approach to the patient with retiform (angulated) purpura"</a> and  <a class="medical medical_review" href="/d/html/1944.html" rel="external">"Calciphylaxis (calcific uremic arteriolopathy)"</a> and  <a class="medical medical_review" href="/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a>.)</p><p></p><p class="headingAnchor" id="H3108290065"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1370576539"><span class="h2">Thromboembolism management</span><span class="headingEndMark"> — </span>Anticoagulation is appropriate for individuals with protein C deficiency who develop a thromboembolic event (<a class="graphic graphic_algorithm graphicRef107766" href="/d/graphic/107766.html" rel="external">algorithm 1</a>). Management is similar to other individuals with a thromboembolism, with the possible exception of measures to reduce the risk of warfarin-induced skin necrosis. These measures may include the use of an anticoagulant other than <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, judicious use of warfarin with a lower-than-average starting dose, and/or longer duration of overlapping heparin/low molecular weight (LMW) heparin administration. (See <a class="local">'Warfarin-induced skin necrosis (management and prevention)'</a> below.)</p><p>The choice between a direct oral anticoagulant (DOAC) versus <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is individualized based on a number of factors including the severity of thrombosis, patient preference, adherence to therapy, and potential drug and dietary interactions. We are more likely to use a DOAC for individuals with typical venous thromboembolism (VTE) presentations, and we are more likely to use LMW heparin for an extended period or warfarin for individuals with concerns about adherence or severe clinical presentations such as hypoxemia/shock or proximal deep vein thrombosis (DVT) with an extensive clot burden.</p><p>The duration of anticoagulation is individualized according to the age of the patient, site and clinical significance of the thromboembolism, and whether the thromboembolism was provoked or unprovoked. Indefinite anticoagulation is recommended for many patients with an unprovoked thromboembolic event, regardless of whether an inherited thrombophilia is identified; the documentation of protein C deficiency may strengthen the case for indefinite anticoagulation particularly if there is a strong family history of VTE. Factors to consider in deciding on the duration of anticoagulation are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p>If it is decided to use a DOAC for the long-term prevention of recurrent VTE, we generally continue a higher dose regimen (eg, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> 20 mg once daily or <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> 5 mg twice daily rather than rivaroxaban 10 mg once daily or apixaban 2.5 mg twice daily), assuming the individual's bleeding risk is not excessive. This is because protein C deficiency is one of the more thrombophilic of the hereditary thrombophilias. The prescribing physician and patient should understand that evidence for the optimal dose in such patients is lacking.</p><p class="headingAnchor" id="H470565701"><span class="h2">Warfarin-induced skin necrosis (management and prevention)</span><span class="headingEndMark"> — </span>As noted above, warfarin-induced skin necrosis is a potential complication of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy in patients with protein C deficiency caused by transient hypercoagulability during warfarin initiation. (See <a class="local">'Warfarin-induced skin necrosis'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute treatment</strong> – It is important to establish that skin necrosis is due to protein C deficiency rather than another cause such as vasculitis, calciphylaxis, or heparin-induced thrombocytopenia (HIT) (see <a class="local">'Differential diagnosis'</a> above). In patients with known protein C deficiency (or a known family history of protein C deficiency) and skin necrosis, a presumptive diagnosis of warfarin-induced skin necrosis can be made while protein C levels are being obtained. In patients without a known personal or family history of protein C deficiency, consultation with a specialist with expertise in thrombophilia may help in determining the likelihood of protein C deficiency.</p><p></p><p class="bulletIndent1">Once the diagnosis is made, immediate intervention is required to prevent rapid progression and to minimize complications. The following should be done without delay:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discontinue <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administer <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> intravenously.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administer <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> (therapeutic dose). (See  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administer a source of protein C such as <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a> (eg, Ceprotin, not available in all centers) or Fresh Frozen Plasma (FFP) [<a href="#rid84">84,85</a>]. The required volume of FFP may be great depending on the patient’s baseline protein C activity level.</p><p></p><p class="bulletIndent1">In some cases, skin lesions may continue to progress despite these interventions due to tissue infarction. The therapies should be continued; involvement of a dermatologist and/or surgeon may also be required.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Patients with protein C deficiency who require an anticoagulant have several options for reducing the risk of warfarin-induced skin necrosis. Interventions may be individualized depending on clinical factors and patient values and preferences. If <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is administered, it should be started at a low dose (eg, 2 mg daily for the first three days followed by gradually increasing increments of an additional 2 to 3 mg until therapeutic anticoagulation is achieved).</p><p></p><p class="bulletIndent1">Additional options include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of an anticoagulant other than <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> (eg, a DOAC such as <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, or <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Overlapping of heparin with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> during the first several days of warfarin administration</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Retreatment with </strong><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> – Patients with a history of warfarin-induced skin necrosis have been successfully retreated with warfarin after an episode of warfarin-induced skin necrosis; in such cases, <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a> should be used until a stable level of anticoagulation is established [<a href="#rid56">56,86</a>]. However, use of a DOAC would circumvent these issues. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p></p><p>Of note, <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a> is different from recombinant activated protein C, a product that was tested and found to be ineffective in the treatment of sepsis. As discussed below, prophylactic protein C concentrate may also be appropriate for prophylaxis in other settings (eg, perioperative, peripartum) in especially high-risk individuals. Additional information about protein C concentrate is provided separately. (See  <a class="medical medical_review" href="/d/html/7925.html" rel="external">"Plasma derivatives and recombinant DNA-produced coagulation factors", section on 'Protein C'</a>.)</p><p class="headingAnchor" id="H2507001255"><span class="h2">Neonatal purpura fulminans management</span><span class="headingEndMark"> — </span>This subject is discussed separately. (See  <a class="medical medical_review" href="/d/html/5911.html" rel="external">"Neonatal thrombosis: Management and outcome", section on 'Neonatal purpura fulminans'</a>.)</p><p class="headingAnchor" id="H3221151144"><span class="h2">Patients without thrombosis (eg, obstetrical/surgical management)</span><span class="headingEndMark"> — </span>Individuals with protein C deficiency who have not had a thromboembolic event may benefit from avoiding conditions that increase thrombotic risk (eg, estrogen-containing contraceptives, prolonged immobility) and from the judicious use of prophylactic anticoagulation in certain settings (<a class="graphic graphic_algorithm graphicRef107766" href="/d/graphic/107766.html" rel="external">algorithm 1</a>). In addition, some individuals with an especially high risk of thrombosis (eg, individuals with severe thrombotic phenotypes, homozygosity for a protein C defect) may be treated with prophylactic <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a> (Ceprotin) around the time of surgery or delivery. Close consultation with a specialist who has expertise in the management of inherited thrombophilias is advised.</p><p>Recommendations for alternative contraceptives and for anticoagulation in high-risk settings are presented in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraception</strong> – (See  <a class="medical medical_review" href="/d/html/5479.html" rel="external">"Contraception: Counseling for women with inherited thrombophilias"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – (See  <a class="medical medical_review" href="/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'Adverse pregnancy outcome risk'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery</strong> – Protein C deficiency confers three points on the modified Caprini score (<a class="graphic graphic_table graphicRef83739" href="/d/graphic/83739.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute medical illness</strong> – (See  <a class="medical medical_review" href="/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a>.)</p><p></p><p class="headingAnchor" id="H3427050064"><span class="h2">Testing of first-degree relatives</span><span class="headingEndMark"> — </span>The testing of asymptomatic first-degree relatives can be delayed until after puberty and is generally most helpful in settings in which the risk of thrombosis is increased, such as initiation of oral hormonal contraceptives or pregnancy. This subject is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1364.html" rel="external">"Screening for inherited thrombophilia in asymptomatic adults"</a>.)</p><p class="headingAnchor" id="H1006408413"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114614.html" rel="external">"Society guideline links: Anticoagulation"</a>.)</p><p class="headingAnchor" id="H23517046"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – Protein C is a vitamin K-dependent anticoagulant protein synthesized in the liver. Upon activation, protein C inactivates coagulation factors Va and VIIIa, which are necessary for thrombin generation and factor X activation (<a class="graphic graphic_figure graphicRef110320" href="/d/graphic/110320.html" rel="external">figure 1</a>). Most patients with inherited protein C deficiency are heterozygous for a genetic defect that reduces protein C levels, activity, or both (ie, transmission is autosomal dominant). A number of acquired conditions also can reduce protein C levels, including disseminated intravascular coagulation (DIC), liver disease, <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> antagonist (VKA) anticoagulants, meningococcal infection, and others. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – The prevalence of inherited protein C deficiency is approximately 0.2 to 0.5 percent in the general population and 2 to 5 percent in individuals with venous thromboembolism (VTE) (<a class="graphic graphic_table graphicRef108016" href="/d/graphic/108016.html" rel="external">table 1</a>). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation </strong>– Individuals with hereditary protein C deficiency lack the natural anticoagulant function of activated protein C and are at risk for clinical phenotypes associated with increased thrombotic risk including VTE, warfarin-induced skin necrosis, and (in homozygotes) neonatal purpura fulminans. There may also be an association with stroke although this risk is likely to be small. Individuals identified by population screening may have no other clinical manifestations besides low protein C activity levels. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of protein C deficiency may be suspected in a patient with recurrent venous thrombosis, thrombosis in an unusual vascular bed (eg, portal, hepatic, mesenteric, cerebral), thrombosis at a young age (eg, &lt;50 years), strong family history of VTE, and/or warfarin-induced skin necrosis. The diagnosis is established by laboratory testing that reveals protein C activity below the lower limit of normal in the laboratory performing the testing. Typical values in heterozygotes are approximately 50 percent of normal. A number of assays are available; none of the available assays will be accurate during <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy, and some clotting-based assays may also be affected by other anticoagulants. Consultation with the testing laboratory may be advisable. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1">Appropriate settings in which to test for protein C deficiency are presented separately:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children – (See  <a class="medical medical_review" href="/d/html/5920.html" rel="external">"Thrombophilia testing in children and adolescents"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancy – (See  <a class="medical medical_review" href="/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Patients with VTE – (See  <a class="medical medical_review" href="/d/html/1363.html" rel="external">"Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Patients with stroke – (See  <a class="medical medical_review" href="/d/html/1083.html" rel="external">"Overview of the evaluation of stroke", section on 'Blood tests'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Patients without thrombosis – (See  <a class="medical medical_review" href="/d/html/1364.html" rel="external">"Screening for inherited thrombophilia in asymptomatic adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of protein C deficiency includes other inherited and acquired thrombophilias and other causes of skin necrosis such as vasculitis and heparin-induced thrombocytopenia. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>VTE</strong> – Anticoagulation is appropriate for individuals with protein C deficiency who develop a thromboembolic event, similar to all patients with a thrombosis; this should be continued indefinitely in most patients with an unprovoked VTE unless there is a reason not to do so (<a class="graphic graphic_algorithm graphicRef107766" href="/d/graphic/107766.html" rel="external">algorithm 1</a>). The choice between a direct oral anticoagulant (DOAC) versus <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is based on a number of factors including the severity of thrombosis, patient preference, adherence to therapy, and potential drug and dietary interactions. (See <a class="local">'Thromboembolism management'</a> above and  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Skin necrosis</strong> – For warfarin-induced skin necrosis, immediate intervention is required to prevent rapid progression and to minimize complications. <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> should be discontinued, <a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">vitamin K</a> and therapeutic heparin anticoagulation administered, and <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a> or Fresh Frozen Plasma (FFP) given. Options for prevention include use of an alternative anticoagulant, heparin coverage, or protein C concentrate prophylaxis. (See <a class="local">'Warfarin-induced skin necrosis (management and prevention)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Purpura fulminans</strong> – Management of neonatal purpura fulminans is presented separately. (See  <a class="medical medical_review" href="/d/html/5911.html" rel="external">"Neonatal thrombosis: Management and outcome", section on 'Neonatal purpura fulminans'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Patients without a personal history of thrombosis may benefit from avoiding conditions that increase thrombotic risk and from the judicious use of prophylactic anticoagulation in certain settings (<a class="graphic graphic_algorithm graphicRef107766" href="/d/graphic/107766.html" rel="external">algorithm 1</a>). In addition, some individuals with an especially high risk of thrombosis may be treated with prophylactic <a class="drug drug_general" data-topicid="10094" href="/d/drug information/10094.html" rel="external">protein C concentrate</a> perioperatively and in the peripartum period. Close consultation with a specialist who has expertise in the management of inherited thrombophilias is advised. (See <a class="local">'Patients without thrombosis (eg, obstetrical/surgical management)'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med 1986; 314:1298.</a></li><li><a class="nounderline abstract_t">Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109:3161.</a></li><li><a class="nounderline abstract_t">Danese S, Vetrano S, Zhang L, et al. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010; 115:1121.</a></li><li><a class="nounderline abstract_t">Reverdiau-Moalic P, Delahousse B, Body G, et al. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood 1996; 88:900.</a></li><li><a class="nounderline abstract_t">Karpatkin M, Mannuccio Mannucci P, Bhogal M, et al. Low protein C in the neonatal period. Br J Haematol 1986; 62:137.</a></li><li><a class="nounderline abstract_t">Mannucci PM, Vigano S. Deficiencies of protein C, an inhibitor of blood coagulation. Lancet 1982; 2:463.</a></li><li><a class="nounderline abstract_t">Polack B, Pouzol P, Amiral J, Kolodie L. Protein C level at birth. Thromb Haemost 1984; 52:188.</a></li><li><a class="nounderline abstract_t">Manco-Johnson MJ, Marlar RA, Jacobson LJ, et al. Severe protein C deficiency in newborn infants. J Pediatr 1988; 113:359.</a></li><li><a class="nounderline abstract_t">Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317:991.</a></li><li><a class="nounderline abstract_t">Reitsma PH, Bernardi F, Doig RG, et al. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 73:876.</a></li><li><a class="nounderline abstract_t">Reitsma PH, Poort SR, Allaart CF, et al. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. Blood 1991; 78:890.</a></li><li><a class="nounderline abstract_t">D'Ursi P, Marino F, Caprera A, et al. ProCMD: a database and 3D web resource for protein C mutants. BMC Bioinformatics 2007; 8 Suppl 1:S11.</a></li><li><a class="nounderline abstract_t">Tang L, Guo T, Yang R, et al. Genetic background analysis of protein C deficiency demonstrates a recurrent mutation associated with venous thrombosis in Chinese population. PLoS One 2012; 7:e35773.</a></li><li><a class="nounderline abstract_t">Foster DC, Yoshitake S, Davie EW. The nucleotide sequence of the gene for human protein C. Proc Natl Acad Sci U S A 1985; 82:4673.</a></li><li><a class="nounderline abstract_t">Plutzky J, Hoskins JA, Long GL, Crabtree GR. Evolution and organization of the human protein C gene. Proc Natl Acad Sci U S A 1986; 83:546.</a></li><li><a class="nounderline abstract_t">Romeo G, Hassan HJ, Staempfli S, et al. Hereditary thrombophilia: identification of nonsense and missense mutations in the protein C gene. Proc Natl Acad Sci U S A 1987; 84:2829.</a></li><li><a class="nounderline abstract_t">Aiach M, Gandrille S, Emmerich J. A review of mutations causing deficiencies of antithrombin, protein C and protein S. Thromb Haemost 1995; 74:81.</a></li><li><a class="nounderline abstract_t">Petrini P, Segnestam K, Ekelund H, Egberg N. Homozygous protein C deficiency in two siblings. Pediatr Hematol Oncol 1990; 7:165.</a></li><li><a class="nounderline abstract_t">Lind B, Johnsen AH, Thorsen S. Naturally occurring Arg(-1) to His mutation in human protein C leads to aberrant propeptide processing and secretion of dysfunctional protein C. Blood 1997; 89:2807.</a></li><li><a class="nounderline abstract_t">Inoue H, Terachi SI, Uchiumi T, et al. The clinical presentation and genotype of protein C deficiency with double mutations of the protein C gene. Pediatr Blood Cancer 2017; 64.</a></li><li class="breakAll">https://databases.lovd.nl/shared/variants/PROC/unique.</li><li><a class="nounderline abstract_t">Griffin JH, Mosher DF, Zimmerman TS, Kleiss AJ. Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood 1982; 60:261.</a></li><li><a class="nounderline abstract_t">Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41:553.</a></li><li><a class="nounderline abstract_t">Angchaisuksiri P. Coagulopathy in malaria. Thromb Res 2014; 133:5.</a></li><li><a class="nounderline abstract_t">Smith OP, White B, Vaughan D, et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997; 350:1590.</a></li><li><a class="nounderline abstract_t">Fourrier F, Lestavel P, Chopin C, et al. Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med 1990; 16:121.</a></li><li><a class="nounderline abstract_t">Rintala E, Seppälä OP, Kotilainen P, et al. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med 1998; 26:965.</a></li><li><a class="nounderline abstract_t">White B, Livingstone W, Murphy C, et al. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96:3719.</a></li><li><a class="nounderline abstract_t">Faioni EM, Franchi F, Krachmalnicoff A, et al. Low levels of the anticoagulant activity of protein C in patients with chronic renal insufficiency: an inhibitor of protein C is present in uremic plasma. Thromb Haemost 1991; 66:420.</a></li><li><a class="nounderline abstract_t">Warkentin TE, Cook RJ, Sarode R, et al. Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome. Blood 2015; 126:486.</a></li><li><a class="nounderline abstract_t">Mitchell CA, Rowell JA, Hau L, et al. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Engl J Med 1987; 317:1638.</a></li><li><a class="nounderline abstract_t">Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost 1997; 23:271.</a></li><li><a class="nounderline abstract_t">al-Mugeiren MM, Gader AM, al-Rasheed SA, et al. Coagulopathy of childhood nephrotic syndrome--a reappraisal of the role of natural anticoagulants and fibrinolysis. Haemostasis 1996; 26:304.</a></li><li><a class="nounderline abstract_t">Mannucci PM, Valsecchi C, Bottasso B, et al. High plasma levels of protein C activity and antigen in the nephrotic syndrome. Thromb Haemost 1986; 55:31.</a></li><li><a class="nounderline abstract_t">MacCallum PK, Cooper JA, Martin J, et al. Associations of protein C and protein S with serum lipid concentrations. Br J Haematol 1998; 102:609.</a></li><li><a class="nounderline abstract_t">Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73:87.</a></li><li><a class="nounderline abstract_t">Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77:444.</a></li><li><a class="nounderline abstract_t">Gladson CL, Scharrer I, Hach V, et al. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59:18.</a></li><li><a class="nounderline abstract_t">Heijboer H, Brandjes DP, Büller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323:1512.</a></li><li><a class="nounderline abstract_t">Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353.</a></li><li><a class="nounderline abstract_t">Koster T, Rosendaal FR, Briët E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85:2756.</a></li><li><a class="nounderline abstract_t">Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 1983; 309:340.</a></li><li><a class="nounderline abstract_t">Wintzen AR, Broekmans AW, Bertina RM, et al. Cerebral haemorrhagic infarction in young patients with hereditary protein C deficiency: evidence for "spontaneous" cerebral venous thrombosis. Br Med J (Clin Res Ed) 1985; 290:350.</a></li><li><a class="nounderline abstract_t">de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ 1998; 316:589.</a></li><li><a class="nounderline abstract_t">Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68:1370.</a></li><li><a class="nounderline abstract_t">Horellou MH, Conard J, Bertina RM, Samama M. Congenital protein C deficiency and thrombotic disease in nine French families. Br Med J (Clin Res Ed) 1984; 289:1285.</a></li><li><a class="nounderline abstract_t">Bovill EG, Bauer KA, Dickerman JD, et al. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989; 73:712.</a></li><li><a class="nounderline abstract_t">Koeleman BP, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol 1997; 34:256.</a></li><li><a class="nounderline abstract_t">Mustafa S, Mannhalter C, Rintelen C, et al. Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. Blood Coagul Fibrinolysis 1998; 9:85.</a></li><li><a class="nounderline abstract_t">Aiach M, Borgel D, Gaussem P, et al. Protein C and protein S deficiencies. Semin Hematol 1997; 34:205.</a></li><li><a class="nounderline abstract_t">Lensen RP, Rosendaal FR, Koster T, et al. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 1996; 88:4205.</a></li><li class="breakAll">Broekmans AW, Bertina RM. Protein C. In: Recent Advances in Blood Coagulation, Poller L (Ed), Churchill Livingstone, New York 1985. Vol 4, p.117.</li><li><a class="nounderline abstract_t">Vigano D'Angelo S, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986; 77:416.</a></li><li><a class="nounderline abstract_t">Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest 1987; 80:1535.</a></li><li><a class="nounderline abstract_t">McGehee WG, Klotz TA, Epstein DJ, Rapaport SI. Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 1984; 101:59.</a></li><li><a class="nounderline abstract_t">Zauber NP, Stark MW. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med 1986; 104:659.</a></li><li><a class="nounderline abstract_t">Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol 1993; 129:766.</a></li><li><a class="nounderline abstract_t">Pourdeyhimi N, Bullard Z. Warfarin-induced skin necrosis. Hosp Pharm 2014; 49:1044.</a></li><li><a class="nounderline abstract_t">Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol 2009; 61:325.</a></li><li><a class="nounderline abstract_t">Teepe RG, Broekmans AW, Vermeer BJ, et al. Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency. Arch Dermatol 1986; 122:1408.</a></li><li><a class="nounderline abstract_t">Sallah S, Abdallah JM, Gagnon GA. Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency. Haemostasis 1998; 28:25.</a></li><li><a class="nounderline abstract_t">Makris M, Bardhan G, Preston FE. Warfarin induced skin necrosis associated with activated protein C resistance. Thromb Haemost 1996; 75:523.</a></li><li><a class="nounderline abstract_t">Kohler J, Kasper J, Witt I, von Reutern GM. Ischemic stroke due to protein C deficiency. Stroke 1990; 21:1077.</a></li><li><a class="nounderline abstract_t">Grewal RP, Goldberg MA. Stroke in protein C deficiency. Am J Med 1990; 89:538.</a></li><li><a class="nounderline abstract_t">Camerlingo M, Finazzi G, Casto L, et al. Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology 1991; 41:1371.</a></li><li><a class="nounderline abstract_t">Douay X, Lucas C, Caron C, et al. Antithrombin, protein C and protein S levels in 127 consecutive young adults with ischemic stroke. Acta Neurol Scand 1998; 98:124.</a></li><li><a class="nounderline abstract_t">Munts AG, van Genderen PJ, Dippel DW, et al. Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol 1998; 245:21.</a></li><li><a class="nounderline abstract_t">Ganesan V, McShane MA, Liesner R, et al. Inherited prothrombotic states and ischaemic stroke in childhood. J Neurol Neurosurg Psychiatry 1998; 65:508.</a></li><li><a class="nounderline abstract_t">Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348:913.</a></li><li><a class="nounderline abstract_t">Brenner B, Blumenfeld Z. Thrombophilia and fetal loss. Blood Rev 1997; 11:72.</a></li><li><a class="nounderline abstract_t">Sarig G, Lanir N, Hoffman R, Brenner B. Protein C global assay in the evaluation of women with idiopathic pregnancy loss. Thromb Haemost 2002; 88:32.</a></li><li><a class="nounderline abstract_t">Pabinger I, Allaart CF, Hermans J, et al. Hereditary protein C-deficiency: laboratory values in transmitters and guidelines for the diagnostic procedure. Report on a study of the SSC Subcommittee on Protein C and Protein S. Protein C Transmitter Study Group. Thromb Haemost 1992; 68:470.</a></li><li><a class="nounderline abstract_t">Bertina RM, Broekmans AW, Krommenhoek-van Es C, van Wijngaarden A. The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemost 1984; 51:1.</a></li><li><a class="nounderline abstract_t">Comp PC, Nixon RR, Esmon CT. Determination of functional levels of protein C, an antithrombotic protein, using thrombin-thrombomodulin complex. Blood 1984; 63:15.</a></li><li><a class="nounderline abstract_t">Michiels JJ, Hamulyák K. Laboratory diagnosis of hereditary thrombophilia. Semin Thromb Hemost 1998; 24:309.</a></li><li><a class="nounderline abstract_t">Bovill EG, Tomczak JA, Grant B, et al. Protein CVermont: symptomatic type II protein C deficiency associated with two GLA domain mutations. Blood 1992; 79:1456.</a></li><li><a class="nounderline abstract_t">Faioni EM, Esmon CT, Esmon NL, Mannucci PM. Isolation of an abnormal protein C molecule from the plasma of a patient with thrombotic diathesis. Blood 1988; 71:940.</a></li><li><a class="nounderline abstract_t">Sala N, Borrell M, Bauer KA, et al. Dysfunctional activated protein C (PC Cádiz) in a patient with thrombotic disease. Thromb Haemost 1987; 57:183.</a></li><li><a class="nounderline abstract_t">Sala N, Owen WG, Collen D. Functional assay for protein C in human plasma. Thromb Res 1984; 32:605.</a></li><li><a class="nounderline abstract_t">Bertina RM, Broekmans AW, van der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemost 1982; 48:1.</a></li><li><a class="nounderline abstract_t">Pabinger I, Kyrle PA, Speiser W, et al. Diagnosis of protein C deficiency in patients on oral anticoagulant treatment: comparison of three different functional protein C assays. Thromb Haemost 1990; 63:407.</a></li><li><a class="nounderline abstract_t">Jones DW, Mackie IJ, Winter M, et al. Detection of protein C deficiency during oral anticoagulant therapy--use of the protein C:factor VII ratio. Blood Coagul Fibrinolysis 1991; 2:407.</a></li><li><a class="nounderline abstract_t">O'Brien AE, Tate GM, Shiach C. Evaluation of protein C and protein S levels during oral anticoagulant therapy. Clin Lab Haematol 1998; 20:245.</a></li><li class="breakAll">prescribing information for this product is available at the following website: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=22370 (Accessed on November 17, 2011).</li><li><a class="nounderline abstract_t">Schramm W, Spannagl M, Bauer KA, et al. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol 1993; 129:753.</a></li><li><a class="nounderline abstract_t">De Stefano V, Mastrangelo S, Schwarz HP, et al. Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb Haemost 1993; 70:247.</a></li></ol></div><div id="topicVersionRevision">Topic 1354 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3010107" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The regulation of hemostasis: the protein C system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17110453" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The cytoprotective protein C pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20018912" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8704247" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evolution of blood coagulation activators and inhibitors in the healthy human fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3753649" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Low protein C in the neonatal period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6125639" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Deficiencies of protein C, an inhibitor of blood coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6549231" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Protein C level at birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3397801" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Severe protein C deficiency in newborn infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3657866" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Absence of thrombosis in subjects with heterozygous protein C deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7482420" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1868249" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17430555" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : ProCMD: a database and 3D web resource for protein C mutants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22545135" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genetic background analysis of protein C deficiency demonstrates a recurrent mutation associated with venous thrombosis in Chinese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2991887" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The nucleotide sequence of the gene for human protein C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3511471" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evolution and organization of the human protein C gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2437584" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hereditary thrombophilia: identification of nonsense and missense mutations in the protein C gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8578531" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A review of mutations causing deficiencies of antithrombin, protein C and protein S.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2206858" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Homozygous protein C deficiency in two siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9108399" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Naturally occurring Arg(-1) to His mutation in human protein C leads to aberrant propeptide processing and secretion of dysfunctional protein C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28111891" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The clinical presentation and genotype of protein C deficiency with double mutations of the protein C gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28111891" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The clinical presentation and genotype of protein C deficiency with double mutations of the protein C gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6896290" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15726661" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24099998" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Coagulopathy in malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9393338" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2139671" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9590329" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Protein C in the treatment of coagulopathy in meningococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11090052" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1796390" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Low levels of the anticoagulant activity of protein C in patients with chronic renal insufficiency: an inhibitor of protein C is present in uremic plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25979950" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3683503" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A fatal thrombotic disorder associated with an acquired inhibitor of protein C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9255908" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Thromboembolic risks and complications in nephrotic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8979144" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Coagulopathy of childhood nephrotic syndrome--a reappraisal of the role of natural anticoagulants and fibrinolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3754658" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : High plasma levels of protein C activity and antigen in the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9695981" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Associations of protein C and protein S with serum lipid concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7740502" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prevalence of protein C deficiency in the healthy population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9065991" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2966450" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2146503" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746774" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7742536" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6688122" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3917815" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cerebral haemorrhagic infarction in young patients with hereditary protein C deficiency: evidence for "spontaneous" cerebral venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9518910" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6895379" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Deficiency of protein C in congenital thrombotic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6437521" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Congenital protein C deficiency and thrombotic disease in nine French families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2521802" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The clinical spectrum of heterozygous protein C deficiency in a large New England kindred.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9241710" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Familial thrombophilia: a complex genetic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9607123" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9241706" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Protein C and protein S deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8943855" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8943855" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3511097" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3680513" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6547283" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Coumarin necrosis associated with hereditary protein C deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3754407" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8507082" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Coumarin-induced skin necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25673894" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Warfarin-induced skin necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19615543" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Warfarin-induced skin necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3789774" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9885367" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8701423" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Warfarin induced skin necrosis associated with activated protein C resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2195715" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ischemic stroke due to protein C deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2220892" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Stroke in protein C deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1891083" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9724011" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Antithrombin, protein C and protein S levels in 127 consecutive young adults with ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9457624" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Coagulation disorders in young adults with acute cerebral ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9771774" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Inherited prothrombotic states and ischaemic stroke in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8843809" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Increased fetal loss in women with heritable thrombophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9242990" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Thrombophilia and fetal loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12152673" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Protein C global assay in the evaluation of women with idiopathic pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1448781" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hereditary protein C-deficiency: laboratory values in transmitters and guidelines for the diagnostic procedure. Report on a study of the SSC Subcommittee on Protein C and Protein S. Protein C Transmitter Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6547008" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6317087" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Determination of functional levels of protein C, an antithrombotic protein, using thrombin-thrombomodulin complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9763348" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Laboratory diagnosis of hereditary thrombophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1347706" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Protein CVermont: symptomatic type II protein C deficiency associated with two GLA domain mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2965607" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Isolation of an abnormal protein C molecule from the plasma of a patient with thrombotic diathesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3037717" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Dysfunctional activated protein C (PC Cádiz) in a patient with thrombotic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Functional assay for protein C in human plasma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6897135" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Protein C deficiency in a Dutch family with thrombotic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2402742" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Diagnosis of protein C deficiency in patients on oral anticoagulant treatment: comparison of three different functional protein C assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1932526" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Detection of protein C deficiency during oral anticoagulant therapy--use of the protein C:factor VII ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9777272" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Evaluation of protein C and protein S levels during oral anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9777272" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Evaluation of protein C and protein S levels during oral anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8507079" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8236128" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
